Meeting
2023 ASCO Annual Meeting
Tumor infiltrating lymphocyte (TIL) harvest and ex vivo expansion from primary and metastatic (met) uveal melanoma (UM) tumors.
Authors
Sapna Pradyuman Patel
The University of Texas MD Anderson Cancer Center, Houston, TX
Sapna Pradyuman Patel , Marie-Andree Forget , Firas Y. Kreidieh , Meredith Pelster , Michael A. Davies , Rodabe Navroze Amaria , Dan S. Gombos , Chantale Bernatchez
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT00338377
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9513)
DOI
10.1200/JCO.2023.41.16_suppl.9513
Abstract #
9513
Poster Bd #
276
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Successful tumor-infiltrating lymphocyte (TIL) growth from uveal melanoma (UM) using a three-signal (3.0) method.
First Author: Meredith Pelster
Poster
2024 ASCO Annual Meeting
Dynamics of circulating cytokines and chemokines during and after tumor-infiltrating lymphocyte cell therapy with lifileucel in advanced melanoma patients.
First Author: Rongsu Qi
Poster
2023 ASCO Annual Meeting
Effect of a novel expansion process on tumor-infiltrating lymphocyte (TIL) polyfunctionality, cytotoxicity, and expansion, while preserving cells in a less differentiated and more stem-like phenotype.
First Author: Andrew Yuhas
Poster
2023 ASCO Annual Meeting
A phase 3 study (TILVANCE-301) to assess the efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, in combination with pembrolizumab compared with pembrolizumab alone in patients with untreated unresectable or metastatic melanoma.
First Author: Daniel Olson